ClinicalTrials.gg
RecruitingNCT06150950Updated Jan 5, 2026

REHAB Fontan Failure: A Trial of Cardiac Rehabilitation

An interventional study of Cardiac rehabilitation and Usual care in Heart Failure Congenital and Single-ventricle, sponsored by Stanford University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Univentricular Heart with a site in United States — 13 open to participants now, 16 under way, none of them phase 3. Univentricular Heart · United States.

Planned enrollment
9th of 32
50 · median 24
Started
2024
with 3 others
No phase
17 of 55
6 open now
Primary completion
2026-12
later than 4 of 15 live
Registered
45th of 55
by date
Lead sponsor
3 of 55
Stanford University

Among the 55 studies in Univentricular Heart with a site in United States, this one is the 9th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2024, is one of 17 with no phase, reaches primary completion later than 4 of the 15 other live ones, and was the 45th registered.

Univentricular Heart

86 studies on the registry are indexed under Univentricular Heart; 22 are open to participants now.

Browse Univentricular Heart studies →

Open to participants now

13 of the 55 studies in Univentricular Heart with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Univentricular Heart studies recruiting now, 8 (38%) set no upper age limit and 13 (62%) stop at 75 or younger; 16 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Univentricular Heart with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the impact of cardiac rehabilitation on Fontan failure patients' exertional tolerance, frailty, and quality of life.

  1. Among patients with Fontan failure, will cardiac rehabilitation increase average daily steps compared to usual care?
  2. Among patients with Fontan failure, will cardiac rehabilitation improve exertional tolerance (as measured by cardiopulmonary exercise testing), frailty, and self-reported quality of life metrics compared to usual care?
Read the detailed description

REHAB Fontan Failure is a a multi-center, non-blinded, randomized clinical trial evaluating the effect of cardiac rehabilitation compared to usual care on exercise tolerance among adults with Fontan failure. Eligible study subjects will be identified from clinical chart review and study informational fliers will be sent to Adult Congenital Heart Disease (ACHD) cardiologists at all centers. Fontan failure patients being evaluated for outpatient care at ACHD centers and meeting eligibility criteria will be enrolled and randomly assigned to either cardiac rehabilitation or usual clinical care.

03

Conditions studied

  • Heart Failure Congenital
  • Single-ventricle

Browse trials for

Keywords

  • Fontan
  • Single ventricle
  • Cardiac rehabilitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fontan failure, defined as history of a Fontan procedure and at least one of the following: systemic ventricular EF \<50% (by echocardiography, cardiac magnetic resonance imaging, or computer tomography), protein losing enteropathy, plastic bronchitis, chronic loop diuretics prescribed by ACHD Cardiologist, and/or peak VO2 \< 50% predicted (by FRIEND equation)
  • Age >= 18 years old

Exclusion criteria

Exclusion Criteria:

  • Inotrope-dependence
  • Symptomatic, uncontrolled arrhythmias
  • Pregnancy
  • to cardiac rehab or already enrolled in cardiac rehabilitation
  • Inability to comply with the protocol
  • Recent (\<3 months) planned Fontan pathway percutaneous or surgical intervention
  • Resting hypoxemia with baseline oxygen saturation \<80%
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Cardiac rehabilitation

    For patient randomized to cardiac rehabilitation, the ACHD clinician will place the referral after they and the patient have seen the group assignment. All participants will be referred to Heart Fit for Life community-based cardiac rehabilitation program in Palo Alto, CA. Cardiac rehabilitation will be offered as an in-person, hybrid, or completely virtual program for Stanford participants and will be entirely virtual for Vanderbilt participants. Participants will attend 3 sessions per week for 12 weeks. Participants will receive weekly email reminders via the electronic medical record to encourage participation. The study protocol pertains only to referral to cardiac rehabilitation. All other aspects of the cardiac care will be at the discretion of clinicians. All study participants will receive a Fitbit for daily activity tracking.

    Behavioral: Cardiac rehabilitation

  • Active comparator
    Usual care

    For patients randomized to the usual care (no cardiac rehabilitation group), cardiac rehabilitation will not be initiated between randomization and for up to 16 weeks following randomization. The study protocol controls only referral to cardiac rehabilitation. All other aspects of the cardiac care, such as titration of guideline directed medical therapy will be at the discretion of clinicians. All study participants will receive a Fitbit for daily activity tracking.

    Other: Usual care

Interventions

  • BehavioralCardiac rehabilitation

    Cardiac rehabilitation is a multifaceted, comprehensive therapeutic intervention of personalized, supervised exercise training that is beneficial and well-studied among patients with non-ACHD heart failure and has consistently been shown to improve QOL. Unfortunately, cardiac rehabilitation has been underutilized with an overall participation \<50% of eligible patients despite international guidelines advocating for more consistent deployment of cardiac rehabilitation. A major a barrier to cardiac rehabilitation is access, as CMS-mandates a physician be within 3 minutes of the rehabilitation facility to assure insurance reimbursement. This mandate limits isolated, outpatient cardiac rehabilitation programs, especially in rural communities.

  • OtherUsual care

    For participants randomized to the usual care (no cardiac rehabilitation group), cardiac rehabilitation will not be initiated between randomization and for up to 16 weeks following randomization. The study protocol controls only referral to cardiac rehabilitation. All other aspects of the cardiac care, such as titration of guideline directed medical therapy will be at the discretion of clinicians.

06

What researchers measure

Primary outcomes

  1. Average daily step count

    Average daily step count during the intervention period measured by Fitbit 3 activity tracker

    Time frame: 120 days (+/- 45 days) post-randomization

Secondary outcomes

  1. Change in 5-meter timed walk as a measure of slowness

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  2. Change in exercise time as a measure of exhaustion

    Exercise time on cardiopulmonary exercise testing

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  3. Change in respiratory exchange ratio (RER) as a measure of exhaustion

    RER on cardiopulmonary exercise testing (exhaustion)

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  4. Change in mini-nutritional assessment short form (MNA-SF) score

    Nutrition score as measured by MNA-SF; range 0-14; malnourished 0-7, 8-11 at-risk, and 12-14 normal nutritional status

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  5. Change in body fat percentage

    Body fat percentage is a measure of body composition

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  6. Change in grip strength

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  7. Change in patient reported physical activity questionnaire score

    The physical activity questionnaire score ranges from 0 - 10,000 kilo-calories/week, with higher scores representing higher physical activity.

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  8. Change in Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) scale score

    KCCQ-12 is a 12 question questionnaire, participants completed questionnaire about how heart failure affected their life over the past 2 weeks. The scale has 4 domains: symptom frequency, physical limitation, social limitations and quality of life for a total possible transformed score of 0 to 100 where 100 denotes the highest health status. A positive change from baseline indicates improvement.

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  9. Change Patient Health Questionnaire-2 (PHQ-2) score

    Mood assessment (Range 0-6, higher score indicates higher risk of depression, \>=3 suggestive of depression)

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  10. Average daily active minutes

    Total average daily active minutes from Fitbit

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  11. Average daily active minutes of moderate-high intensity activity

    Average daily active minutes of moderate-high intensity activity from Fitbit

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  12. Average daily sedentary minutes

    Average daily sedentary minutes from Fitbit

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  13. Change in peak respiratory oxygen uptake (VO2)

    Peak VO2 on follow-up cardiopulmonary exercise testing, adjusted for baseline

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  14. Change in oxygen (O2) pulse

    O2 pulse on follow-up cardiopulmonary exercise testing, adjusted for baseline

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  15. Change in minute ventilation/carbon dioxide production (VE/VCO2)

    VE/VCO2 on follow-up cardiopulmonary exercise testing, adjusted for baseline

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

  16. Change in anaerobic threshold

    Anaerobic threshold on follow-up cardiopulmonary exercise testing, adjusted for baseline

    Time frame: Baseline and 120 days (+/- 45 days) post-randomization

Other outcomes

  1. Exploratory outcome: number of participants with exercise-induced clinical ailment

    Sustained arrhythmia or hemodynamic change necessitating hospitalization, heart failure hospitalization, or all-cause death within 30 days of completion of cardiac rehabilitation

    Time frame: 120 days (+/- 45 days) post-randomization

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 20 interventional studies with no phase under Univentricular Heart, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 63. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2023
First posted
Nov 30, 2023
StartActual
May 5, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06150950
Collaborators
Vanderbilt University Medical Center, Adult Congenital Heart Association, Julie Fletcher Memorial Fund, Pete Huttlinger Memorial Fund
Responsible party
Daniel Clark (Assistant Professor of Adult and Pediatric Cardiology, Stanford University) — Principal investigator
First posted
Nov 30, 2023
Start date
May 5, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 5, 2026

Study contacts

Daniel E Clark, MD, MPH
principal investigator · Stanford University
Jonathan N Menachem, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion